Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Optimal Duration of Anticoagulation Therapy for Low-risk Pulmonary Embolism Patients With Cancer

NCT04724460 is registered in ClinicalTrials.gov with Takeshi Morimoto as lead sponsor.

NCT NCT04724460
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04724460 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Optimal Duration of Anticoagulation Therapy for Low-risk Pulmonary Embolism Patients With Cancer
Lead sponsor
Takeshi Morimoto
Phase
Phase 4
Overall status
Completed
Start date
February 18, 2021
Completion date
December 31, 2024
Enrollment
179 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anticoagulants, neoplasms, venous thrombosis